Ketorolac 0.45% Ophthalmic Solution

@article{McCormack2011Ketorolac0O,
  title={Ketorolac 0.45% Ophthalmic Solution},
  author={P. L. McCormack},
  journal={Drugs & Aging},
  year={2011},
  volume={28},
  pages={583-589}
}
  • P. L. McCormack
  • Published 2011
  • Medicine
  • Drugs & Aging
    • Ketorolac 0.45% ophthalmic solution is a topical NSAID indicated in the US for the treatment of ocular pain and inflammation following cataract surgery.In animal studies, the ocular relative bioavailability of single-dose topical ketorolac 0.45% ophthalmic solution was 2- to 3-fold higher than that of ketorolac 0.4% ophthalmic solution.In two identically designed, randomized, double-masked, multicentre trials in adult patients undergoing cataract extraction, the proportions of patients with a… CONTINUE READING
    View on Springer
    ncbi.nlm.nih.gov
    Top 3 of 9 Citations
    Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use
    M. Amon, M. BusinInternational Ophthalmology2012
    33
    Comparing the Efficacy of Ophthalmic NSAIDs in Common Indications
    D. Wilson, Scott M Schutte, S. R. AbelThe Annals of pharmacotherapy2015
    29
    Artificial tears alone versus 0.45% ketorolac tromethamine with artificial tears for the treatment of acute viral conjunctivitis.
    Adriana Falcão Veloso Lyra, Lílian Correia Bastos, … T. ArantesArquivos brasileiros de oftalmologia2014
    5
    9 Citations
    Citation Type

    Citation Type

    Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use
    • 33
    • PDF
    Comparing the Efficacy of Ophthalmic NSAIDs in Common Indications
    • 29
    Artificial tears alone versus 0.45% ketorolac tromethamine with artificial tears for the treatment of acute viral conjunctivitis.
    • 5
    • PDF
    Moving Past Anti-VEGF: Novel Therapies for Treating Diabetic Retinopathy
    • 52
    • PDF
    Intranasal Ketorolac
    • 4
    Diabetic retinopathy: a complex pathophysiology requiring novel therapeutic strategies
    • 22
    Ketorolac Tromethamine Spray Prevents Postendotracheal-Intubation-Induced Sore Throat after General Anesthesia
    • 6
    • PDF
    Current options and emerging therapies for anterior ocular inflammatory disease
    • 7
    Non-steroidal anti-inflammatory drugs ( NSAIDs ) in ophthalmology : pharmacological and clinical characteristics
    • 2
    • PDF

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 16 REFERENCES
    Comparative effects of ketorolac 0.5% or diclofenac 0.1% ophthalmic solutions on inflammation after cataract surgery.
    • 48
    Twice-daily, preservative-free ketorolac 0.45% for treatment of inflammation and pain after cataract surgery.
    • 38
    Ketorolac. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management.
    • 313
    Comparison of the efficacy and safety of ketorolac tromethamine 0.5% and prednisolone acetate 1% after cataract surgery.
    • 45
    Comparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for inflammation after phacoemulsification: Prospective randomized double‐masked study
    • 41
    An update on the use of ophthalmic ketorolac tromethamine 0.4%
    • 27
    The Role of NSAIDs in the Management of Postoperative Ophthalmic Inflammation
    • 87
    Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery: Prospective randomized double‐masked clinical trial
    • 37
    • PDF
    Ocular pharmacokinetics of 0.45% ketorolac tromethamine
    • 24
    • PDF
    Efficacy and tolerability of preservative-free and preserved diclofenac and preserved ketorolac eyedrops after cataract surgery.
    • 28